Exploiting Synergy in Chronic Myelogenous Leukemia: A Phase Ib Evaluation of Dasatinib plus Cyclosporine in patients with Ph+ leukemia refractory to or intolerant of imatinib mesylate (ESCAPE1b Trial)

Objective

Clinical trial of the investigational drug combination dasatinib and cyclosporine given by mouth.

IRB Protocol Number

10-1401

Principal Investigator(s)

CHRISTOPHER PORTER

Cancer Trials

• Leukemia/Myelodysplasia

Sponsor(s)

Childrens Hospital Colorado

Contact

NICOLE HAGELSTROM at 720-848-7262
or NICOLE.IVERSON@UCDENVER.EDU

Eligibility and Other Participant Information

What To Expect : A screening period to determine eligibility. A treatment period that can last as long as you are responding well to the study drug. A follow up period will consist of a clinic visit after you stop taking the study drug (to follow for any lasting side effects). // Eligibility criteria include but are not limited to 18 years or older with chronic myelogenous leukemia.